Navigation Links
Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Date:5/14/2008

- Two 4-week cohorts will evaluate R7128 1000mg BID in HCV genotype 1 treatment-naive patients and R7128 1500mg BID in HCV genotypes 2 or 3

treatment-experienced patients -

PRINCETON, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) has commenced dosing two additional cohorts of a 4-week Phase 1 study of R7128 in combination with Pegasys(R) (peginterferon alfa-2a) plus Copegus(R) (ribavirin) in both treatment-naive and treatment-experienced patients chronically-infected with hepatitis C virus (HCV) genotypes 1, 2 and 3. R7128, a prodrug of PSI-6130, is a nucleoside analogue polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche.

The purpose of this 4-week study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of R7128 in the clinically-relevant setting of combination therapy for chronic HCV infection. The previously planned Cohort 3 will continue dose-exploration with administration of R7128 1000mg twice-daily (BID) in treatment-naive patients with HCV genotype 1. Cohort 4 will evaluate R7128 1500mg BID administered in combination with Pegasys plus Copegus in treatment-experienced patients with genotypes 2 or 3 who did not achieve a sustained virologic response (SVR) with previous interferon-based therapy.

There will be 25 patients in each dose cohort with 20 patients randomized to receive R7128 and 5 patients randomized to receive placebo. After completing 4 weeks of the triple combination regimen and a follow-up period of 4 weeks of Pegasys plus Copegus, patients will receive an additional 16 to 40 weeks of open-label dosing of Pegasys plus Copegus under a separate protocol to complete the stand
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
10. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
11. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker.c...available in its catalogue: ,, United States D...5 ,, http://www.reportlinker.com/p0158733/Uni...casts-to-2015.html ,, United States Dental Dev...Summary ,, This report is an essential source ...
(Date:11/25/2009)..., WALTHAM, Mass., Nov. 25 Accordin...uthority on medical technology market intelligence...ion devices will continue to see rapid growth over...lowdown. MRG,s US Markets for Trauma Devices 20...ly dynamic over the next five years, with competit...
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker.c...available in its catalogue: ,, Intranasal Drug...://www.reportlinker.com/p0164267/Intranasal-Drug-D...he US intranasal drug delivery market is witnessin...e delivery of conventional local therapeutic drugs...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 13US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5Sperm May Play Role in Transmission of HIV 60062 1Waste in the U S Healthcare System Pegged at 24700 Billion in Report From Thomson Reuters 60058 1Waste in the U S Healthcare System Pegged at 24700 Billion in Report From Thomson Reuters 60058 2AMERIGROUP Announces Preliminary Third Quarter Results 60054 1AMERIGROUP Announces Preliminary Third Quarter Results 60054 2AMERIGROUP Announces Preliminary Third Quarter Results 60054 3AMERIGROUP Announces Preliminary Third Quarter Results 60054 4AMERIGROUP Announces Preliminary Third Quarter Results 60054 5
...agen, Inc. (Amex: ILE ) today announced that th...ation (BLA) for Isolagen Therapy(TM), a novel, fir...wrinkles/nasolabial folds, to the U.S. Food and Dr...solabial folds Phase III trials were conducted und...BLA submission is a significant regulatory milesto...
...um Therapeutics (NYSE Alternext US: CXM) and its o...orted that positive clinical findings demonstratin...lized manual cooling techniques during robotic-ass...hed in the April 2009 issue of Urology and is no...article/S0090-4295(08)01953-5/abstract . The Hyp...
Other Medicine Technology:Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration 2Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration 3Isolagen, Inc. Submits Biologics License Application for the Treatment of Wrinkles to the U.S. Food and Drug Administration 4Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 2Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 3Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 4Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 5Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 6Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 7Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology 8
(Date:11/27/2009)... Shamir Optical Industry...vider of innovative products and technology to the...board of directors had declared a dividend distrib...proximately NIS 37.62 million based on the Novembe...proximately US$ 0.609 (approximately NIS 2.3 based...
(Date:11/27/2009)...ade; announced today that Spectrum Health (Grand R...rise orthopedic templating solution and its Trauma... (PRWEB) November 27, 2009 -- Voyant Health&... Rapids, Michigan) has licensed its TraumaCad Ente...maCad Extend workflow solution, to allow its ortho...
(Date:11/26/2009)...Newswire/ -- The diabetes population in the United...and annual medical spending on the disease is proj...day, according to a study published in the Decembe...g Diabetes ® Program (NCDP), a program of Nov...m the University of Chicago. ,, According to th...
(Date:11/26/2009)...from the North Pole, Textsanta.net lets parents si... North Pole, AK (PRWEB) --... at the North Pole Santa Claus has added SMS text ... informed of his Christmas progress at the North P...t have identified a large and growing percentage o...
(Date:11/25/2009)...ire-USNewswire/ -- When most people hear the acron...ractor can also give patients the help they need. ...h is where your jaw (mandible) contacts/connects w...mmon symptoms associated with TMJ dysfunction are ... But many other symptoms can be caused from TMJ d...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...gar sitting on the surface of cancer cells are key...h treating and stopping the spread of certain type...tate, breast, ovarian and lung, among others. Arm...anco, M.D., Ph.D., and her co-workers at the Moore...
...to condemn hurtful comments, study suggests , ...eople overestimate how strongly they would react t...-three percent of study participants at York Unive...nts about the black person when he left the room. ...
.... 8 Allscripts-Misys Healthcare,Solutions, Inc., ...lscripts or,the Company), today announced its fina...ovember 30, 2008. , (Logo: http://www.newscom...gacy Allscripts for the period of October 11, 2008...
...Jan. 8 A new educational Web site offers expert p...cal products and medical devices from the Agency f...ducation and Research on Therapeutics (CERTs), a f...IN ) http://www.chainonline.org links clinicians...
... Jan. 8 Heska Corporation (Nasdaq: HSKA ) annou...eska Corporation Invites You to Join Its Fourth Qu...ference Call on the Web, When: Monday, Marc... website)., How: Live over the Internet --...
...orist Missile Strikes , , NEW YORK, Jan. 8 Unit...ions of North America today committed to raise $10...in southern Israel, part of a major initiative to ...he funds will enhance programs supported by the An...
Other Medicine News:Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Many Turn Blind Eye to Racism 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:UJC and Jewish Federations of North America Commit $10 Million for Needs in Southern Israel 2
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
...ratory and a worldwide leader in innovative labora...nsive test menu of highly complex and unique medic... by the University of Utah, ARUP Laboratories' cli...sity teaching hospitals and children's hospitals, ...
Medicine Products: